Difluprednate Eye Drops Recalled for Defective Container Compromising Sterility
CIPLA is recalling 3,468 bottles of Difluprednate Ophthalmic Emulsion nationwide due to defective protective caps that could expose the dropper tip and compromise sterility. No injuries have been reported.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall involving a defective medical container that poses a risk of sterility compromise and potential eye infection. No illnesses or injuries have been reported, meeting the rubric criterion for a score of 3 (risk-of-harm product where injury has not yet been reported).
Plain-English summary
CIPLA is recalling 3,468 bottles of Difluprednate Ophthalmic Emulsion, 0.05%, nationwide due to a manufacturing defect in the protective cap.
The issue stems from defective containers where the protective cap can break or fail to properly seal. This exposes the dropper tip, which could allow contamination and compromise the sterility of the eye drops.
Affected lot is DEG5BD2 with expiration date 07/2023. The product is distributed nationwide across the U.S. in 5 mL bottles marked for prescription use only.
Consumers should stop using affected bottles immediately and contact their healthcare provider or pharmacist. Those with affected lot numbers should return the product to their pharmacy.
The recalled product
- Product
- Difluprednate Ophthalmic Emulsion, 0.05%, 5 mL bottle, RX only, Manufactured for Exelan Pharmecuticals, Inc., Boca Raton, FL 33432, NDC 76282-708-50.
- Manufacturer
- CIPLA
- Hazard
- sterility-compromise
- defective-container
- contamination-risk
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot # DEG5BD2
- Exp 07/2023
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- ModerateGas-X Simethicone 125 mg softgels recall for incomplete labeling
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27